Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Acambis (LSE:ACM; ACAM) Credit Suisse Andrew Sinclair Price target Underperform
Sinclair lowered his target to

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE